Remission of membranoproliferative glomerulonephritis type I with the use of tacrolimus
- PMID: 17609987
- DOI: 10.1007/s00467-007-0523-1
Remission of membranoproliferative glomerulonephritis type I with the use of tacrolimus
Abstract
Membranoproliferative glomerulonephritis, albeit uncommon, is associated with considerable morbidity and mortality in children. Corticosteroids are the mainstay of therapy for severe disease, although data supporting their use are limited. We report our experience in treating two children with nephrotic-nephritic syndrome from idiopathic membranoproliferative glomerulonephritis. Both children experienced a suboptimal response to prolonged courses of steroids and were started on tacrolimus as a steroid-sparing agent. Rapid and complete remission was achieved in both children after initiation of tacrolimus. The purpose of our report is to increase awareness of health care professionals to the potential benefits of this agent in inducing remission in children with severe membranoproliferative glomerulonephritis.
Similar articles
-
Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR.Am J Kidney Dis. 2009 Jul;54(1):51-8. doi: 10.1053/j.ajkd.2009.02.018. Epub 2009 May 5. Am J Kidney Dis. 2009. PMID: 19406543
-
[Evaluation of cyclosporin A efficacy in the treatment of steroid-resistant nephrotic syndrome in the course of membranoproliferative glomerulonephritis--case report].Pol Arch Med Wewn. 2001 Nov;106(5):1065-9. Pol Arch Med Wewn. 2001. PMID: 12026521 Polish.
-
Long-term outcome of children with steroid-resistant nephrotic syndrome treated with tacrolimus.Pediatr Nephrol. 2010 Jun;25(6):1117-24. doi: 10.1007/s00467-010-1471-8. Epub 2010 Mar 9. Pediatr Nephrol. 2010. PMID: 20217433
-
Nephrotic syndrome associated with chronic lymphocytic leukemia resistant to immunosuppressive drugs: remission obtained by splenectomy.Clin Nephrol. 1996 Apr;45(4):273-6. Clin Nephrol. 1996. PMID: 8861805 Review.
-
[Use of Cyclosporine A and new immunosuppressive drugs in the therapy of glomerulonephritis].Przegl Lek. 2001;58(7-8):798-804. Przegl Lek. 2001. PMID: 11769390 Review. Polish.
Cited by
-
Dense deposit disease and the factor H H402 allele.Clin Exp Nephrol. 2008 Jun;12(3):228-32. doi: 10.1007/s10157-008-0031-z. Epub 2008 Jan 26. Clin Exp Nephrol. 2008. PMID: 18224273
-
Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis.Clin Exp Immunol. 2008 Feb;151(2):199-209. doi: 10.1111/j.1365-2249.2007.03558.x. Epub 2007 Dec 7. Clin Exp Immunol. 2008. PMID: 18070148 Free PMC article. Review.
-
C3 Glomerulopathy.Pediatr Nephrol. 2017 Jan;32(1):43-57. doi: 10.1007/s00467-015-3310-4. Epub 2016 Apr 7. Pediatr Nephrol. 2017. PMID: 27056062 Review.
-
Remission of resistant MPGN type I with mycophenolate mofetil and steroids.Pediatr Nephrol. 2009 Mar;24(3):597-600. doi: 10.1007/s00467-008-1023-7. Epub 2008 Oct 30. Pediatr Nephrol. 2009. PMID: 18972137
-
Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies.Biomed Res Int. 2017;2017:2180508. doi: 10.1155/2017/2180508. Epub 2017 May 9. Biomed Res Int. 2017. PMID: 28573137 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources